Abstract: The invention concerns the identification of proteomes of biological fluids and their use in determining the state of maternal/fetal conditions, including maternal conditions of fetal origin, chromosomal aneuploidies, and fetal diseases associated with fetal growth and maturation. In particular, the invention concerns a comprehensive proteomic analysis of human amniotic fluid (AF) and cervical vaginal fluid (CVF), and the correlation of characteristic changes in the normal proteome with various pathologic maternal/fetal conditions, such as intra-amniotic infection, pre-term labor, and/or chromosomal defects. The invention further concerns the identification of biomarkers and groups of biomarkers that can be used for non-invasive diagnosis of various pregnancy-related disorders, and diagnostic assays using such biomarkers.

Abstract: The present invention concerns the identification and detection of biological fluid biomarkers of neonatal sepsis using global proteomic approaches.

Abstract: The invention concerns the identification of proteomes of biological fluids and their use in determining the state of maternal/fetal conditions, including maternal conditions of fetal origin, chromosomal aneuploidies, and fetal diseases associated with fetal growth and maturation. In particular, the invention concerns a comprehensive proteomic analysis of human amniotic fluid (AF) and cervical vaginal fluid (CVF), and the correlation of characteristic changes in the normal proteome with various pathologic maternal/fetal conditions, such as intra-amniotic infection, pre-term labor, and/or chromosomal defects. The invention further concerns the identification of biomarkers and groups of biomarkers that can be used for non-invasive diagnosis of various pregnancy-related disorders, and diagnostic assays using such biomarkers.

Abstract: The invention relates to a method for the early non-invasive diagnosis of fetal aneuploidy. In particular, the invention concerns the diagnosis of fetal aneuploidy by identifying protein expression patterns characteristics of fetal aneuploidy in a maternal biological fluid, such as maternal serum or amniotic fluid.

Abstract: A method is provided for identifying sequences of molecules and sequence modifications from mass spectrometry data. At least one de novo sequence is produced from mass spectrometry data of sequences of molecules,. At least one mass-based alignment is calculated between each de novo sequence and sequences in a sequence database. The molecular masses of molecules in the de novo sequence are compared to molecular masses of molecules in each sequence in the sequence database. Mass differences of modification sites are interpreted between the sequence in the sequence database and the de novo sequence that have been identified by the mass-based alignment as modifications identified in a modification catalog. At least one match score for the mass-based alignment is calculated that provides an indication of matching between the sequence in the sequence database and the de novo sequence. Sequences in the sequence database are identified from mass-based alignments in response to the match scores.

Abstract: Pure nucleic acids encoding novel receptors for bombesin-like peptides, the novel receptors themselves, and their antibodies. Also disclosed is a method of screening for a compound capable of interacting with any of these novel receptors.

Abstract: Pure nucleic acids encoding novel receptors for bombesin-like peptides, the novel receptors themselves, and their antibodies. Also disclosed is a method of screening for a compound capable of interacting with any of these novel receptors.

Abstract: Pure nucleic acids encoding novel receptors for bombesin-like peptides, the novel receptors themselves, and their antibodies. Also disclosed is a method of screening for a compound capable of interacting with any of these novel receptors.

Abstract: A pure DNA encoding a peptide which encodes a novel bombesin-related peptide, i.e., H-pGlu-Gln-Ser-Leu-Gly-Asn-Gin-Trp-Ala-Arg-Gly-His-Phe-Met-NH.sub.2 or Gly-Asn-Gln-Trp-Ala-Arg-Gly-His-Phe-Met-NH.sub.2. Also disclosed are a vector and a cell containing such a DNA, a pharmaceutical composition which includes such a peptide, and a method of preparing such a peptide by recombinant technology.